Trial Information
Allogeneic Tumor Cell Vaccination in Patients With Chronic Myeloid Leukemia
Inclusion Criteria:
- Patients above the age of 55 consenting to participate in the study.
- Patients with documented CML with Philadelphia chromosome t (9:21)
- Patients with no HLA matched sibling.
- Patients eligible for BMT for who no matched unrelated donor can be identified after
completion of an international donor search lasting for more than six months, or
patients that have failed BMT.
- Patients with contra-indication to BMT.
- Patients refusing BMT.
- Patients who failed interferon alpha, ARAc and/or Glivec.
Exclusion Criteria:
- Patients requiring immunosuppressive therapy or corticosteroids.
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Investigate the feasibility of allogeneic tumor cell vaccine for patients with resistant CML.
Principal Investigator
Shimon Slavin, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Hadassah Medical Organization
Authority:
Israel: Israeli Health Ministry Pharmaceutical Administration
Study ID:
191199-HMO-CTIL
NCT ID:
NCT00162513
Start Date:
December 2006
Completion Date:
Related Keywords:
- Chronic Myeloid Leukemia
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
